In the NSCLC cohort, studies by Gettinger et al. (Nivolumab plus Erlotinib in EGFR-mutant NSCLC) and Neal et al. (Atezolizumab plus Cabozantinib had the lowest rates of G3-5 toxicity reported at 19% and 34% respectively (17, 18). Here, EGFR is linked to non-small cell lung carcinoma.